Biography and Research Information
OverviewAI-generated summary
Dr. Donald E. Fry's research focuses on surgical infections and the application of antibiotics in surgical contexts. He has authored over 310 journal publications and 140 book chapters, with a significant body of work addressing the prevention and management of infections associated with surgical procedures. His recent publications include studies on antibiotic prophylaxis in surgery, organizational models for preventing surgical pathway infections, and antibiotic therapy following percutaneous drainage of intra-abdominal abscesses. He has served as Editor-in-Chief of the journal *Surgical Infections* since 2016.
Dr. Fry holds an M.D. from The Ohio State University and completed his general surgery residency at the University of Louisville School of Medicine. He is board-certified by the American Board of Surgery and is a Fellow of the American College of Surgeons and the Infectious Diseases Society of America. His scholarly metrics include an h-index of 42, over 8,400 citations, and more than 310 publications. He is recognized as a high-impact researcher.
In addition to his academic work, Dr. Fry is Professor Emeritus of Surgery from the University of New Mexico School of Medicine, where he previously served as Chairman of the Department of Surgery for nearly 17 years. He is currently an Adjunct Professor of Surgery at Northwestern University Feinberg School of Medicine. He also holds a full-time position as Executive Vice President at Michael Pine and Associates, a healthcare think-tank focused on outcome measurement and alternative payment models.
Metrics
- h-index: 42
- Publications: 313
- Citations: 8,443
Selected Publications
-
Hepatic Phenotype in NBAS‐Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients (2025)
Collaboration Network
Top Collaborators
- Hepatic Phenotype in NBAS‐Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients
- Hepatic Phenotype in NBAS‐Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients
- Hepatic Phenotype in NBAS‐Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients
- Hepatic Phenotype in NBAS‐Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients
- Hepatic Phenotype in NBAS‐Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients
- Hepatic Phenotype in NBAS‐Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients
- Hepatic Phenotype in NBAS‐Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients
- Hepatic Phenotype in NBAS‐Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients
- Hepatic Phenotype in NBAS‐Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients
- Hepatic Phenotype in NBAS‐Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients
- Hepatic Phenotype in NBAS‐Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients
- Hepatic Phenotype in NBAS‐Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients
- Hepatic Phenotype in NBAS‐Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients
- Hepatic Phenotype in NBAS‐Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients
- Hepatic Phenotype in NBAS‐Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients
Similar Researchers
Based on overlapping research topics